MedPath

The Chocolate Touch Study

Not Applicable
Active, not recruiting
Conditions
Ischemia
Intermittent Claudication
Peripheral Artery Disease (PAD)
Interventions
Device: Chocolate Touch
Device: Lutonix Drug Coated Balloon
Registration Number
NCT02924857
Lead Sponsor
TriReme Medical, LLC
Brief Summary

The Chocolate Touch study is a randomized, multi-center, prospective, adaptive study, designed to show sufficient safety and effectiveness of the Chocolate Touch™ for use in superficial femoral or popliteal arteries with the intention of obtaining regulatory approval to market this device in the United States

Detailed Description

The primary objective of the Chocolate Touch study is to demonstrate non-inferior safety and non-inferior effectiveness of the Chocolate Touch™ compared to the Lutonix® drug coated balloon catheter. These data are intended to show safety and effectiveness of the Chocolate Touch sufficient to support regulatory approval to market this device in the United States for use in superficial femoral or popliteal arteries.

Study success is defined as statistical demonstration of the non-inferiority hypothesis tests for both the primary safety and effectiveness hypothesis.

PMA P210039 approval has been granted on 11/04/2022. The study is now in the post-approval phase.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
333
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Test Group (Chocolate Touch)Chocolate Touch* The diameter of the Chocolate Touch should correspond to the diameter of the vessel for treatment with a balloon to artery ratio of 1.1:1. * The Chocolate Touch must be inflated to at least nominal pressure. Maintain balloon inflation for a minimum of 2 minutes. The balloon may be inflated as long as required to achieve optimal angioplasty outcome. * If delivery is attempted and failed, a new Chocolate Touch should be used for subsequent attempts after pre-dilatation.
Control Group (Lutonix Drug Coated Balloon)Lutonix Drug Coated Balloon* Never inflate the Lutonix® Drug Coated Balloon (DCB)prior to reaching the target lesion. * The Lutonix® Catheter should be advanced to the target site as fast as possible (i.e. 30 seconds) and immediately inflated to appropriate pressure to ensure full wall apposition (balloon to artery ratio of \>1:1). * If the deployment of the Lutonix® Catheter exceeds 3 minutes, the catheter requires placement with a new unit. * Maintain balloon inflation for a minimum of 2 minutes (120 seconds). The balloon may be inflated as long as required by standard of care to achieve a good angioplasty outcome.
Primary Outcome Measures
NameTimeMethod
Freedom from Major Adverse Events12 months

Composite of target-limb-related death, major amputation of the target limb, and clinically driven re-intervention of the target limb.

True Drug Coated Balloon Success12 months

A composite endpoint that requires patients to achieve Primary Patency (Peak systolic velocity ratio \<2.4 without the need for clinically driven target lesion revascularization) in the absence of a clinically driven bail-out stent (core lab adjudicated).

Secondary Outcome Measures
NameTimeMethod
By Duplex Ultrasound Core Lab Review6, 12, 24, & 36 months

Patency

By Angiographic Core Lab Review (Acute)1 hour

Procedural Success: Defined as the success of the therapy to achieve \<30% diameter stenosis without a flow-limiting dissection or the need for a stent

By Clinical Assessment6, 12, 24, & 36 months

Occurrence of relevant Adverse Events

Trial Locations

Locations (20)

Lankenau Medical Center

🇺🇸

Wynnewood, Pennsylvania, United States

Emory University

🇺🇸

Atlanta, Georgia, United States

Cardiac and Vascular Institute

🇺🇸

Gainesville, Florida, United States

Mt. Sinai Heart

🇺🇸

New York, New York, United States

Cardiovascular Institute of the South

🇺🇸

Houma, Louisiana, United States

Michigan Outpaitient Vascular Institution

🇺🇸

Dearborn, Michigan, United States

St. Luke's Hospital

🇺🇸

Kansas City, Missouri, United States

Jackson Heart

🇺🇸

Jackson, Mississippi, United States

Univeristy Hospitals Cleveland Medical Center

🇺🇸

Cleveland, Ohio, United States

Columbia University Medical Center / NewYork Presbyterian Hospital

🇺🇸

New York, New York, United States

Pinnacle Health Cardiovascular Institute

🇺🇸

Wormleysburg, Pennsylvania, United States

Mt. Sinai - Miami

🇺🇸

Miami Beach, Florida, United States

Penn State Health Holy Spirit Medical Center

🇺🇸

Camp Hill, Pennsylvania, United States

MIssion Research

🇺🇸

New Braunfels, Texas, United States

Swedish Medical Center

🇺🇸

Seattle, Washington, United States

Medical University of Graz - LKH Univ.-Klinikum Graz

🇦🇹

Graz, Austria

Universitat Herz-Zentrum

🇩🇪

Bad Krozingen, Germany

Angiologie - Hansuchkrankenhaus

🇦🇹

Vienna, Austria

Auckland City Hospital

🇳🇿

Auckland, New Zealand

Waikato Hospital

🇳🇿

Hamilton, New Zealand

© Copyright 2025. All Rights Reserved by MedPath